CVS vs. CYTK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CVS and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CVS | CYTK |
|---|---|---|
| Company Name | CVS Health Corporation | Cytokinetics, Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 83.58 billion USD | 4.41 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | February 21, 1973 | April 30, 2004 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CVS and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CVS | CYTK |
|---|---|---|
| 5-Day Price Return | 3.65% | 4.62% |
| 13-Week Price Return | 1.68% | 14.78% |
| 26-Week Price Return | 21.50% | -20.12% |
| 52-Week Price Return | 18.08% | -34.35% |
| Month-to-Date Return | 6.12% | -2.02% |
| Year-to-Date Return | 46.80% | -21.60% |
| 10-Day Avg. Volume | 8.81M | 1.62M |
| 3-Month Avg. Volume | 9.27M | 1.79M |
| 3-Month Volatility | 30.38% | 42.87% |
| Beta | 0.60 | 0.55 |
Profitability
Return on Equity (TTM)
CVS
5.95%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
CVS’s Return on Equity of 5.95% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
CYTK
-132.03%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
CYTK has a negative Return on Equity of -132.03%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
CVS
1.17%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
CVS’s Net Profit Margin of 1.17% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
CYTK
-3,201.47%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
CYTK has a negative Net Profit Margin of -3,201.47%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
CVS
2.44%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
CVS’s Operating Profit Margin of 2.44% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
CYTK
-2,943.30%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
CYTK has a negative Operating Profit Margin of -2,943.30%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | CVS | CYTK |
|---|---|---|
| Return on Equity (TTM) | 5.95% | -132.03% |
| Return on Assets (TTM) | 1.78% | -43.75% |
| Net Profit Margin (TTM) | 1.17% | -3,201.47% |
| Operating Profit Margin (TTM) | 2.44% | -2,943.30% |
| Gross Profit Margin (TTM) | 13.82% | -- |
Financial Strength
Current Ratio (MRQ)
CVS
0.80
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
CVS’s Current Ratio of 0.80 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CYTK
5.99
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
CYTK’s Current Ratio of 5.99 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CVS
0.86
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
CVS’s Debt-to-Equity Ratio of 0.86 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
CYTK
6.03
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.03, CYTK operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
CVS
3.08
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
CVS’s Interest Coverage Ratio of 3.08 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
CYTK
-16.50
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
CYTK has a negative Interest Coverage Ratio of -16.50. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | CVS | CYTK |
|---|---|---|
| Current Ratio (MRQ) | 0.80 | 5.99 |
| Quick Ratio (MRQ) | 0.62 | 5.89 |
| Debt-to-Equity Ratio (MRQ) | 0.86 | 6.03 |
| Interest Coverage Ratio (TTM) | 3.08 | -16.50 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CVS
4.07%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.07%, CVS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CVS
74.62%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
CVS’s Dividend Payout Ratio of 74.62% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CVS | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 4.07% | 0.00% |
| Dividend Payout Ratio (TTM) | 74.62% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CVS
18.34
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
CVS’s P/E Ratio of 18.34 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
CYTK
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for CYTK is currently unavailable.
Price-to-Sales Ratio (TTM)
CVS
0.22
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, CVS’s P/S Ratio of 0.22 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
CYTK
228.72
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
With a P/S Ratio of 228.72, CYTK trades at a valuation that eclipses even the highest in the Biotechnology industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
CVS
1.13
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
CVS’s P/B Ratio of 1.13 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
CYTK
58.48
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 58.48, CYTK’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | CVS | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 18.34 | -- |
| Price-to-Sales Ratio (TTM) | 0.22 | 228.72 |
| Price-to-Book Ratio (MRQ) | 1.13 | 58.48 |
| Price-to-Free Cash Flow Ratio (TTM) | 13.42 | 76.62 |